These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34218265)

  • 21. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model.
    Song Q; Nasri U; Zeng D
    Front Immunol; 2022; 13():844271. PubMed ID: 35251043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
    Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
    Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease.
    Asano T; Matsuoka KI; Iyama S; Ohashi K; Inamoto Y; Ohwada C; Murata M; Satake A; Yoshida C; Nakase K; Mori Y; Tanimoto M
    Acta Med Okayama; 2016 Oct; 70(5):429-433. PubMed ID: 27777442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
    Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
    Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
    Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
    Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
    Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
    Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study.
    Dal MS; Batgi H; Erkurt MA; Hindilerden IY; Kuku I; Kurtoglu E; Kaya E; Besisik SK; Berber I; Nalcaci M; Ulas T; Altuntas F
    Transfus Apher Sci; 2021 Oct; 60(5):103243. PubMed ID: 34420879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Jaglowski SM; Blazar BR
    Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
    Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
    Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
    Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
    Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.
    Shahzad M; Chaudhary SG; Basit A; Thellman C; Rodriguez L; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2022 Feb; 70():101520. PubMed ID: 34952168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.